Patents by Inventor Jens Sommer
Jens Sommer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240139230Abstract: dsRNAi oligonucleotides can be used in methods for the treatment of NASH, preferably the advanced fibrotic and/or cirrhotic stages thereof, using dosage regimens comprising a loading phase followed by a maintenance phase.Type: ApplicationFiled: October 10, 2023Publication date: May 2, 2024Inventors: Jens Markus BORGHARDT, Marc ABRAMS, Andre BROERMANN, Bob Dale BROWN, Kevin CRAIG, Henryk T. DUDEK, Saskia ERBEL, Boris FERGER, Felix JOST, Martin Lee KOSER, Jihye PARK, Utsav SAXENA, Bernhard SCHMID, Florian SOMMER, Stephan TENBAUM, Ingo UPHUES
-
Publication number: 20240100221Abstract: Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein.Type: ApplicationFiled: July 26, 2023Publication date: March 28, 2024Inventor: Jens Sommer-Knudsen
-
Publication number: 20220008612Abstract: Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein.Type: ApplicationFiled: July 19, 2021Publication date: January 13, 2022Inventor: Jens Sommer-Knudsen
-
Patent number: 11065365Abstract: Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein.Type: GrantFiled: April 23, 2020Date of Patent: July 20, 2021Assignee: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITEDInventor: Jens Sommer-Knudsen
-
Publication number: 20200246504Abstract: Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein.Type: ApplicationFiled: April 23, 2020Publication date: August 6, 2020Inventor: Jens SOMMER-KNUDSEN
-
Patent number: 10653814Abstract: Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein.Type: GrantFiled: December 6, 2016Date of Patent: May 19, 2020Assignee: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITEDInventor: Jens Sommer-Knudsen
-
Publication number: 20190374326Abstract: Expandable sealing means for endoluminal devices have been developed for controlled activation. The devices have the benefits of a low profile mechanism (for both self-expanding and balloon-expanding prostheses), contained, not open, release of the material, active conformation to the “leak sites” such that leakage areas are filled without disrupting the physical and functional integrity of the prosthesis, and on-demand, controlled activation, that may not be pressure activated.Type: ApplicationFiled: June 28, 2019Publication date: December 12, 2019Inventors: Ashish Sudhir MITRA, Martin Kean Chong NG, Pak Man Victor WONG, Ben Colin BOBILLIER, Jens SOMMER-KNUDSEN
-
Publication number: 20170203001Abstract: Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein.Type: ApplicationFiled: December 6, 2016Publication date: July 20, 2017Applicant: ELASTAGEN PTY. LIMITEDInventor: Jens Sommer-Knudsen
-
Patent number: 9611312Abstract: Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein.Type: GrantFiled: November 22, 2011Date of Patent: April 4, 2017Assignee: ELASTAGEN PTY. LIMITEDInventor: Jens Sommer-Knudsen
-
Publication number: 20160194425Abstract: Highly expandable materials have been developed for filling an aneurysm sac and for sealing of endoluminal devices vessel walls. The expandable materials have appropriate chemical and physical properties to withstand radiation, sterilization, or storage in sterilizing solution, without loss of expandable characteristics. The expandable materials may contain protectants, prophylactic, diagnostic, therapeutic, or imaging agents. The expandable materials form a seal that actively conforms to vascular anatomy sealing any leaks that may occur after device implantation. In one embodiment, the technology is used to prevent leaks associated with abdominal aortic aneurysm (AAA) repair, especially for complex AAA repair.Type: ApplicationFiled: January 4, 2016Publication date: July 7, 2016Inventors: Ashish Sudhir Mitra, Jens Sommer Knudsen, Roya Ravarian, Cristina Borras Guardiola, Pak Man Victor Wong
-
Patent number: 9216076Abstract: Expandable sealing means for endoluminal devices have been developed for controlled activation. The devices have the benefits of a low profile mechanism (for both self-expanding and balloon-expanding prostheses), contained, not open, release of the material, active conformation to the “leak sites” such that leakage areas are filled without disrupting the physical and functional integrity of the prosthesis, and on-demand, controlled activation, that may not be pressure activated.Type: GrantFiled: May 21, 2012Date of Patent: December 22, 2015Assignee: Endoluminal Sciences Pty. Ltd.Inventors: Ashish Sudhir Mitra, Martin Kean Chong Ng, Pak Man Victor Wong, Ben Colin Bobillier, Jens Sommer-Knudsen
-
Patent number: 8586315Abstract: A fluorescent protein particle comprising: a particle forming component capable of forming or aggregating into a substantially insoluble protein particle when expressed by a cell; a fluorescent component; and a functional component capable of binding to, or being bound by, a target.Type: GrantFiled: May 28, 2008Date of Patent: November 19, 2013Assignee: Innovative Purification Technologies Pty LtdInventors: Jens Sommer-Knudsen, David Moreland Gibbs
-
Publication number: 20130296528Abstract: Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein.Type: ApplicationFiled: November 22, 2011Publication date: November 7, 2013Applicant: ELASTAGEN PTY LIMITEDInventor: Jens Sommer-Knudsen
-
Publication number: 20130190857Abstract: Expandable sealing means for endoluminal devices have been developed for controlled activation. The devices have the benefits of a low profile mechanism (for both self-expanding and balloon-expanding prostheses), contained, not open, release of the material, active conformation to the “leak sites” such that leakage areas are filled without disrupting the physical and functional integrity of the prosthesis, and on-demand, controlled activation, that may not be pressure activated.Type: ApplicationFiled: August 28, 2012Publication date: July 25, 2013Applicant: Endoluminal Sciences Pty Ltd.Inventors: Ashish Sudhir Mitra, Martin Kean Chong Ng, Pak Man Victor Wong, Ben Colin Bobillier, Jens Sommer-Knudsen
-
Patent number: 8318968Abstract: Process for preparing an alkenylphosphonic acid derivative by reacting a phosphonic acid derivative with an alkyne in the presence of a complex catalyst system and a base whose conjugate acid has a pKa in dimethyl sulfoxide (25° C., 1 bar) of at least 6.Type: GrantFiled: March 17, 2008Date of Patent: November 27, 2012Assignee: BASF SEInventors: Markus Christian Biel, Roland Kessinger, Jens Sommer, Janet Bluemel
-
Publication number: 20120009624Abstract: The invention relates to a protein particle comprising chimeric protein having an aggregating part capable of forming or aggregating into a substantially insoluble protein particle when expressed by a cell; and a functional part capable of binding to, or being bound by, a target compound. Affinity matrixes comprising the protein particle are also provided.Type: ApplicationFiled: December 3, 2007Publication date: January 12, 2012Inventors: Jens Sommer-Knudsen, Moreland D. Gibbs
-
Publication number: 20110017362Abstract: A steel flat product having a Zn—Mg—Al coating. The coating, which in addition to zinc and unavoidable impurities, comprises in wt. %: Mg: 4-8%, Al: 0.5-1.8% and optionally one or more of the following: Si: <2%, Pb: <0.1%, Ti: <0.2%, Ni: <1%, Cu: <1%, Co: <0.3%, Mn: <0.5%, Cr: <0.2%, Sr: <0.5%, Fe: <3%, B: <0.1%, Bi: <0.1%, Cd: <0.1%, REM<0.2%, and Sn<0.5%. The steel flat product according to the invention is not only outstandingly protected against corrosion, but also welds well and coats well with an organic layer applied subsequently. The invention also relates to a method for producing a steel flat product having a Zn—Mg—Al coating.Type: ApplicationFiled: November 3, 2008Publication date: January 27, 2011Applicant: THYSSENKRUPP STEEL EUROPE AGInventors: Wilhelm Warnecke, Manfred Meurer, Jens Sommer, Michael Steinhorst
-
Publication number: 20100240146Abstract: A fluorescent protein particle comprising: a particle forming component capable of forming or aggregating into a substantially insoluble protein particle when expressed by a cell; a fluorescent component; and a functional component capable of binding to, or being bound by, a target.Type: ApplicationFiled: May 28, 2008Publication date: September 23, 2010Applicant: INNOVATIVE PURIFICATION TECHNOLOGIES PTY LTD.Inventors: Jens Sommer-Knudsen, David Moreland Gibbs
-
Publication number: 20100129889Abstract: An affinity matrix comprising a base matrix containing biotin; and a fusion protein attached to the base matrix, wherein the fusion protein contains a matrix binding element capable of binding to the base matrix via biotin and a target binding element capable of binding, or being bound by, at least one target component.Type: ApplicationFiled: August 31, 2007Publication date: May 27, 2010Applicant: INNOVATIVE PURIFICATION TECHNOLOGIES PTY LTDInventor: Jens Sommer-Knudsen
-
Publication number: 20100121092Abstract: Process for preparing an alkenylphosphonic acid derivative by reacting a phosphonic acid derivative with an alkyne in the presence of a complex catalyst system and a base whose conjugate acid has a pKa in dimethyl sulfoxide (25° C., 1 bar) of at least 6.Type: ApplicationFiled: March 17, 2008Publication date: May 13, 2010Applicant: BASF SEInventors: Markus Christian Biel, Roland Kessinger, Jens Sommer, Janet Bluemel